

ASX Release

21 October 2022

Anatara receives firm commitments for approximately \$0.865m in a Successful Placement and launches \$0.832m Entitlement Offer

Key Highlights

- **Firm commitments received for a two tranche Placement reflecting strong support from existing and new institutional and sophisticated investors to raise approximately \$0.865 million (before costs)**
- **A non-underwritten 1 for 3 pro-rata non-renounceable Entitlement Offer launched to raise approximately \$0.832 million to acquire shares at the same price as the placement**
- **Participants in the Placement and the Entitlement Offer will receive a free attaching unquoted option on a 1 for 2 basis, exercisable at \$0.07 and expiring 11 December 2025**
- **Funds will be used to reach interim read-out on the GaRP-IBS 90 patient trial due no later than Q2CY2023, for future project acquisitions and to strengthen Anatara's balance sheet.**

Melbourne, Australia 21 October 2022: Anatara Lifesciences Limited ('**Anatara**' or 'the **Company**') (ASX: ANR) announces that it has received firm commitments from institutional and sophisticated investors for a two tranche Placement of ordinary shares in Anatara; together with the launch of a non-underwritten non-renounceable entitlement offer.

The two tranche Placement is expected to raise a total of approximately \$0.865 million (before costs) (**Placement**). A non-underwritten 1 for 3 pro-rata non-renounceable entitlement offer (**Entitlement Offer**) will also be offered to eligible shareholders in Australia and New Zealand to raise approximately \$0.832 million.

Investors who participate in either the Placement or the Entitlement Offer will receive 1 free attaching unquoted option for every 2 new shares subscribed for (**New Option**), exercisable at \$0.07 and expiring on 11 December 2025.

The first tranche of the Placement will fall within the Company's ASX Listing Rule 7.1 capacity (**Tranche 1**). The second tranche of the Placement will also include investment by Directors and will be subject to shareholders' approval (**Tranche 2**). Placement participants will not be eligible to participate in the Entitlement Offer.

The capital raise will be used to reach interim read-out in the form of a futility analysis on Stage 1 of the GaRP-IBS (Irritable Bowel Syndrome) trial involving 90 participants, with enrolment anticipated to be completed in Q1CY2023 and the analysis no later than Q2CY2023. Funds will also be used for future project acquisitions and to strengthen Anatara's balance sheet.

Anatara' Chairman David Brookes commented, *"It was critical to ensure Anatara is sufficiently capitalised to reach its near-term major share price catalyst of the interim read-out of Stage 1 of the GaRP-IBS trial in the coming months. We have acknowledged the Company's disappointment with the trial delays and have taken the necessary steps to expedite the completion of Stage 1 and to have efficient pathways for future participation and the completion of the overall trial. We are likewise very pleased to see such strong support for Anatara from existing and new investors for this capital raising with raised funds also to be used for future project identification and acquisition."*

Taylor Collison Limited acted as Lead Manager and Candour Advisory Pty Ltd acted as Advisor to the Company.

About the two tranche Placement

The Placement is to be completed in the following two tranches, namely:

Tranche	Number of Shares / Options	Price per Share	Conditions to issue	Proposed issue date
Tranche 1 Placement	10,703,343 ordinary shares (Tranche 1 Placement Shares)	A\$0.035 per Tranche 1 Placement Share to raise a total of A\$374,617 (before costs)	Nil. To be issued under the Listing Rule 7.1 placement capacity.	28 October 2022 following receipt of clear funds.
	5,351,672 options (Tranche 1 Placement Options)	Free attaching to the Tranche 1 Placement Shares on the basis of 1 Tranche 1 Placement Option for every 2 new shares subscribed for	To be issued, following shareholder approval. In excess of the Listing Rule 7.1 placement capacity.	16 December 2022 following receipt of clear funds and shareholder approval.
Tranche 2 Placement	14,010,943 ordinary shares (Tranche 2 Placement Shares)	A\$0.035 per Tranche 2 Placement Share to raise a total of A\$490,383 (before costs)	To be issued, following shareholder approval, to Directors and also to non-related institutional investors. In excess of the Listing Rule 7.1 placement capacity.	16 December 2022 following receipt of clear funds and shareholder approval.
	7,005,472 options (Tranche 2 Placement Options)	Free attaching to the Tranche 2 Placement Shares on the basis of 1 Tranche 2 Placement Option for every 2 new shares subscribed for	To be issued, following shareholder approval, to Directors and also to non-related institutional investors In excess of the Listing Rule 7.1 placement capacity.	16 December 2022 following shareholder approval.



About the Entitlement Offer

Anatara is pleased to offer eligible shareholders with a registered address in Australia and New Zealand the opportunity to subscribe for Anatara shares under a non underwritten 1 for 3 pro-rata non-renounceable Entitlement Offer at the price of \$0.035 per Anatara share (**Offer Price**), being the same price as for the Placement.

The Entitlement Offer of approximately 23,785,207 new fully paid ordinary shares at \$0.035 per Anatara share, will raise approximately \$0.832.

The Offer Price equates to a discount of approximately 23.9% based on the share price of \$0.046 at close of trading on 18th October 2022 and a discount of 29.1% to the 5-day volume weighted average price up to and including 18th October 2022.

Participation in the Entitlement Offer is open to all holders of Anatara shares with a registered address in Australia and New Zealand on the Record Date at 7:00pm (Melbourne time) on Wednesday 26 October 2022. Eligible Shareholders may subscribe for shares in excess of their entitlement under a shortfall offer.

The shares issued under the Entitlement Offer will rank equally in all respects with Anatara's existing fully paid ordinary shares.

More information regarding the Entitlement Offer will be set out in the Prospectus to be circulated to eligible shareholders in accordance with the timetable of Key Dates below. The Prospectus will be accessible from the ASX and Anatara's website, <https://anataralifesciences.com/investors/asx-announcements> and www.asx.com.au today, 21 October 2022.

Existing Option holders will not be able to participate in the Entitlement Offer unless they have become entitled to exercise their options in Anatara under the terms of their issue and do so, so they are registered as holders of Share (underlying those options) prior to the Record Date.

The Entitlement Offer will include the ability for Eligible Shareholders to apply for additional shares not taken up by other Eligible Shareholders.

Key Dates

Indicative Timetable for the Entitlement Offer and Placement	
Activity	Date
Prospectus lodgement date Lodgement of Prospectus for the Entitlement Offer and the offer of all Tranche 1 Placement Options and Tranche 2 Placement Options	21 October 2022
Record Date - Entitlement Offer Record Date for Eligible Shareholders for Entitlement Offer	7:00 p.m. 26 October 2022
Issue Date – Tranche 1 Placement Shares Expected issue of Tranche 1 Placement Shares	28 October 2022
Prospectus despatched Despatch of Prospectus for Entitlement Offer and offer of Tranche 1 Placement Options and Tranche 2 Placement Options	31 October 2022
Opening Date Opening Date for the Entitlement Offer Opening Date for the offer of Tranche 1 Placement Options and Tranche 2 Placement Options	31 October 2022
Closing Date	21 November 2022

Closing Date for the Entitlement Offer Closing Date for the offer of Tranche 1 Placement Options and Tranche 2 Placement Options	
Issue Date – Entitlement Offer (Shares and Options) Issue of the Shares and Options under the Entitlement Offer	28 November 2022
Quotation date – Entitlement Offer - Shares Expected ASX quotation of Entitlement Offer Shares	29 November 2022
General Meeting Extraordinary General Meeting for approval of Tranche 2 Placement Shares and Tranche 1 and Tranche 2 Placement Options.	12 December 2022
Issue Date - Tranche 1 Placement Options, Tranche 2 Placement Shares and Tranche 2 Placement Options Issue date of Tranche 1 Placement Options, Tranche 2 Placement Shares and Tranche 2 Placement Options	16 December 2022
Quotation Date – Tranche 2 Placement Shares ASX quotation of the Tranche 2 Placement Shares	19 December 2022

We look forward to keeping the market updated with further material progress.

This announcement has been approved by the Board of Anantara Lifesciences Limited.

—ENDS—

For more information please contact:

General inquiries	
David Brookes Chair, Anantara Lifesciences Ltd +61 (0) 411 712 579 dbrookes@anantara.com	Dirk van Dissel Candour Advisory – Investor Relations +61 (0) 408 326 367 dirk@candouradvisory.com.au

About Anantara Lifesciences Ltd

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

